Scientific Program

 

Scientific Program

Please click on the day to see the full scientific program of that day.

Thursday, October 12, 2017click to expand

14:00 - 14:15 Opening ceremony

Chairs: JJ Kiladjian (France) & C Harrison (United Kingdom)

14:15 - 15:45 SCIENTIFIC SESSION

Molecular pathogenesis and diagnosis

Chairs: JJ Kiladjian (France) & C Harrison (United Kingdom) 

Molecular pathogenesis of MPN
Tony Green
Practical use of molecular tests in MPN diagnosis and beyond
Radek Skoda
New WHO proposals for diagnostic criteria of MPN
Tiziano Barbui
  • Molecular pathogenesis of MPN
    AR Green (United Kingdom)
  • Practical use of molecular tests in MPN diagnosis and beyond
    R Skoda (Switzerland)
  • New WHO proposals for diagnostic criteria of MPN
    T Barbui (Italy)
  • Common mutations but many diseases unravelling the basis for phenotype
    I Plo (France)
15:45 - 16:15 Coffee break

16:15 - 17:00 DEBATE

Classical Philadelphia negative MPN represent a disease continuum and we should no longer use the terms ET, PV and PMF

Chairs: M Griesshammer (Germany) & T Barbui (Italy)
  • In favor
    AR Green (United Kingdom)
  • Against
    G Birgegård (Sweden)
17:00 - 18:30 SCIENTIFIC SESSION

Indolent MPN

Chairs: M Griesshammer (Germany) & T Barbui (Italy)
  • Risk stratification in ET and PV
    M Griesshammer (Germany)
  • Aspirin or not for MPN
    S Giraudier (France)
  • State of the art management of ET
    C Besses (Spain)
  • State of the art management of PV
    J Samuelsson (Sweden)
19:30 - 20:30 Welcome reception

Friday, October 13, 2017click to expand

09:00 - 11:00 CLINICAL CASES

Clinical Cases (interactive)

Chairs: G Birgegård (Sweden) & R Skoda (Switzerland)

The young ET/PV patient
C Harrison (United Kingdom)
Accelerated phase MF
J Mascarenhas
Guidelines for ET, and their utility
J Schwarz
Pregnancy
M Griesshammer(Germany)
Atypical CML
A Almeida(Spai
  • The young ET/PV patient
    C Harrison (United Kingdom)
  • Accelerated phase MF
    J Mascarenhas (USA)
  • Guidelines for ET, and their utility
    J Schwarz (Czech Republic)
  • Pregnancy
    M Griesshammer (Germany)
  • Atypical CML
    A Almeida (Spain)
11:00 - 11:30 Coffee break

11:30 - 12:30 SCIENTIFIC SESSION

Session details to be announced

12:30 - 14:00 Lunch

14:00 - 15:20 SCIENTIFIC SESSION

Myelofibrosis

Chairs: to be announced

  • Current management of myelofibrosis
    JJ Kiladjian (France)
  • Novel therapies of myelofibrosis
    J Mascarenhas (USA)
  • Who should be transplanted and how?
    D McLornan (United Kingdom)
  • Patients with elevated blasts and post MF AML
    L Adès (France)

15:20 - 16:15 DEBATE

Patients with early MF should be treated

Chairs: to be announced

  • In favor
    T Barbui (Italy)
  • Against
    C Harrison (United Kingdom)
16:15 - 16:45 Coffee break

16:45 - 18:00 SCIENTIFIC SESSION

Current status of interferon

Chairs: JJ Kiladjian (France) & LY Shih (Taiwan)

  • Biology of interferon
    I Plo (France)
  • Clinical studies
    H Gisslinger (Austria)
  • The future of IFN in MPNs
    JJ Kiladjian (France)

Saturday, October 14, 2017click to expand

09:00 - 11:00 SCIENTIFIC SESSION

State of the art in rare MPN

Chairs: T Devos (Belgium) & LY Shih (Taiwan)

Eosinophilia: unravelling the mystery
A Reiter (Germany)
Advances in diagnosis and management of CMML
A Almeida (Spain)
State of the art investigation and management of erythrocytosis 
MF McMullin
Novel data
C Besses (Spain
  • Eosinophilia: unravelling the mystery
    A Reiter (Germany)
  • Advances in diagnosis and management of CMML
    A Almeida (Spain)
  • State of the art investigation and management of erythrocytosis
    MF McMullin (United Kingdom)
  • Novel data
    C Besses (Spain)
  • Panel discussion
    All speakers

11:00 - 11:30 Coffee break

11:30 - 12:20 SCIENTIFIC SESSION

State of the art in rare MPN (continued)

Chairs: A Almeida (Spain) & MF McMullin (United Kingdom)

  • Mastocytosis: a complex but not so rare disease
    A Reiter (Germany)
  • Familial MPN
    I Plo (France)